Alexion Pharmaceuticals Inc. (ALXN)

130.21
NASDAQ : Health Technology
Prev Close 134.21
Day Low/High 130.10 / 134.90
52 Wk Low/High 92.56 / 140.77
Avg Volume 1.71M
Exchange NASDAQ
Shares Outstanding 223.47M
Market Cap 29.99B
EPS 0.30
P/E Ratio 383.46
Div & Yield N.A. (N.A)
Alexion To Present At The 26th Annual Credit Suisse Healthcare Conference

Alexion To Present At The 26th Annual Credit Suisse Healthcare Conference

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at the 26th Annual Credit Suisse Healthcare Conference in Scottsdale, AZ on Tuesday, November 7, 2017 at 10:20 a.

Celgene, Bristol-Myers Drop on Poor Earnings as Big Pharma Takes It on the Chin

Celgene, Bristol-Myers Drop on Poor Earnings as Big Pharma Takes It on the Chin

Alexion Pharmaceuticals, Bristol-Myers Squibb and Celgene were among the healthcare firms that unveiled quarterly numbers on Oct. 26.

Alexion Reports Third Quarter 2017 Results

Alexion Reports Third Quarter 2017 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the third quarter of 2017.

Alexion Pharmaceuticals Stock Jumps on FDA Approval of Soliris

Alexion Pharmaceuticals Stock Jumps on FDA Approval of Soliris

The treatment is for adult patients with generalized myasthenia gravis (gMG).

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.

(Photo: Business Wire)

(Photo: Business Wire)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.

Alexion Pharmaceuticals Achieves #54 Analyst Rank, Surpassing Masco

Alexion Pharmaceuticals Achieves #54 Analyst Rank, Surpassing Masco

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Alexion Pharmaceuticals Inc. has taken over the #54 spot from Masco Corp.

Alexion To Report Third Quarter 2017 Results On Thursday, October 26, 2017

Alexion To Report Third Quarter 2017 Results On Thursday, October 26, 2017

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the third quarter 2017 on Thursday, October 26, 2017 before the US financial markets open.

Alexion Adds Paul A. Friedman, M.D. To Its Board Of Directors

Alexion Adds Paul A. Friedman, M.D. To Its Board Of Directors

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Paul A.

Interim Analysis From Phase 3 Open-Label Extension Study Shows Sustained Benefits Of Soliris® (Eculizumab) Treatment For Patients With Refractory Generalized Myasthenia Gravis

Interim Analysis From Phase 3 Open-Label Extension Study Shows Sustained Benefits Of Soliris® (Eculizumab) Treatment For Patients With Refractory Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today results from an interim analysis of an ongoing Phase 3 open-label extension study of the pivotal, placebo-controlled REGAIN study of Soliris ® (eculizumab)...

Alexion Could Target Sage, Ra Pharma: Analyst

Alexion Could Target Sage, Ra Pharma: Analyst

BMO Capital Markets analyst M. Ian Somaiya says Alexion could view Sage Therapeutics and Ra Pharmaceuticals as potential acquisition targets. Somaiya pointed to Sage's diverse pipeline and Ra's diversified complement pipeline.

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

The Dow, S&P 500 and Nasdaq score new records on Tuesday, Sept. 12, as the promise of tax reform fuels gains in the financials sector.

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Stocks returned to session highs as Apple Inc. lays out its latest product launches, including a new version of its smartwatch and iPhone. Here's where stocks are trading Tuesday afternoon.

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks edged higher in cautious gains after Monday's rally pulled the Dow Jones Industrial Average and S&P 500 to their best gains in six months.

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk

Stocks come off of highs on Tuesday, Sept. 12, as a tech sector in wait-and-see mode countered gains in the financial sector. Here's where stocks are trading at market open on Tuesday.

Alexion Pharmaceuticals Slashes 20% of Its Workforce So It Could Boost Profits

Alexion Pharmaceuticals Slashes 20% of Its Workforce So It Could Boost Profits

The resulting financial flexibility will allow Alexion to reinvest $100 million per year in R&D.

Alexion Announces Restructuring To Advance Corporate Strategy

Alexion Announces Restructuring To Advance Corporate Strategy

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced an operational plan to re-align the global organization with its refocused corporate strategy.

Alexion To Host Call To Discuss Restructuring To Advance Corporate Strategy At 8:30 A.m. On September 12, 2017

Alexion To Host Call To Discuss Restructuring To Advance Corporate Strategy At 8:30 A.m. On September 12, 2017

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that the Company will issue a press release on its restructuring to advance its corporate strategy on Tuesday, September 12, 2017 at 8:00 a.

Alexion To Present At Upcoming Investor Conferences

Alexion To Present At Upcoming Investor Conferences

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at two upcoming investor conferences: Morgan Stanley 15th Annual Global Healthcare Conference in New York on Tuesday,...

Alexion Pharmaceuticals Becomes #31 Most Shorted Nasdaq 100 Component, Replacing Paychex

Alexion Pharmaceuticals Becomes #31 Most Shorted Nasdaq 100 Component, Replacing Paychex

The most recent short interest data has been released for the 08/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Rally May Soon Hit a Wall

D.C. drama has been quiet -- too quiet.

Alexion Receives Three New U.S. Patents For Soliris® (eculizumab), Extending Patent Protection Into 2027

Alexion Receives Three New U.S. Patents For Soliris® (eculizumab), Extending Patent Protection Into 2027

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the United States Patent and Trademark Office (USPTO) has issued U.

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence

Achillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence

Thursday's downgrade is in part based on a lack of confidence in Achillion's CH-4471 to compete with Alexion Pharmaceuticals' Soliris treatment.

Alexion And Sema4 Partner In Rare Disease Diagnostics And Systems Biology

Alexion And Sema4 Partner In Rare Disease Diagnostics And Systems Biology

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Sema4 today announced a strategic partnership to leverage their shared experience in data science and systems biology to accelerate rare disease diagnosis and therapeutic...

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Alexion Pharmaceuticals, United Therapeutics and Gilead Sciences were among the biotech stock movers in premarket trading on July 27.

Alexion Reports Second Quarter 2017 Results

Alexion Reports Second Quarter 2017 Results

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the second quarter of 2017.

Alexion Pharmaceuticals Takes Over #120 Spot From Range Resources

Alexion Pharmaceuticals Takes Over #120 Spot From Range Resources

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Alexion Pharmaceuticals Inc. has taken over the #120 spot from Range Resources Corp , according to ETF Channel.

Can Alexion Pharamaceuticals See an Upside Breakout?

Can Alexion Pharamaceuticals See an Upside Breakout?

A quantitative upgrade and chart patterns may do the trick.

TheStreet Quant Rating: C (Hold)